reports
Merus gibt Finanzergebnisse für das erste Quartal 2025 bekannt und inf...
Merus gibt Finanzergebnisse für das erste Quartal 2025 bekannt und informiert über den aktuellen Geschäftsverlauf - Phase-II-Studie mit Petosemtamab in Kombination mit Pembrolizumab in der Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierenden Kopf-Hals-Plattenepithelkarzinoms läuft, Aktualisierung der klinischen Daten auf der ASCO®-Jahrestagung 2025 - Basierend auf dem aktuellen Geschäftsplan des Unternehmens, den vorhandenen Barmitteln, Barmitteläquivalenten und handelbaren Wertpapieren wird erwartet, dass die Geschäftstätigkeit von Merus bis ins Jahr 2028 finanziert w...
Merus annonce ses résultats financiers pour le premier trimestre 2025 ...
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - Essai de phase II portant sur le pétosemtamab en association avec le pembrolizumab en 1re ligne de traitement dans le CETC r/m exprimant PD-L1 en cours et données cliniques mises à jour lors de la réunion annuelle 2025 de l’ASCO® - Sur la base de l’actuel plan de marche de la Société, la trésorerie, les équivalents de trésorerie et les titres négociables existants devraient permettre de financer les activités de Merus jusqu’en 2028 UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusett...
Merus hält einen Vortrag auf der BofA Securities 2025 Health Care Conf...
Merus hält einen Vortrag auf der BofA Securities 2025 Health Care Conference UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 08, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute bekanntgegeben, dass Dr. Bill Lundberg, President und Chief Executive Officer von Merus, an einem Kamingespräch auf der BofA Securities 2025 Health Care Conference am Donnerstag, 15. Mai 2025, um 8:40 Uhr PT/11:40 Uhr ET teilnehmen wird. Der Webcast der Präsentation wird zeit...
Merus participera à la conférence BofA Securities 2025 sur les soins d...
Merus participera à la conférence BofA Securities 2025 sur les soins de santé UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachussets, 08 mai 2025 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS), entreprise spécialisée en oncologie développant des anticorps de pleine longueur multispécifiques (Biclonics® et Triclonics®), a annoncé aujourd’hui que le Dr Bill Lundberg, Président et PDG de Merus, participera à une discussion informelle lors de la conférence BofA Securities 2025 sur les soins de santé, qui se tiendra le mardi 15 mai 2025 à 8h40 heure du Pacifique et à 11h40 heure de l’Est. Le webcast d...
Merus to Present at BofA Securities 2025 Health Care Conference
Merus to Present at BofA Securities 2025 Health Care Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET. The webcast of the presentation will be contemporaneously available on the of the Company'...
The Tile Shop Reports First Quarter 2025 Results
The Tile Shop Reports First Quarter 2025 Results MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles today announced results for its first quarter ended March 31, 2025. First Quarter 2025 Summary Net Sales Decreased 4.1%Comparable Store Sales Decreased 4.0% Gross Margin of 66.0%Net Income of $0.2 Million and Adjusted EBITDA of $4.6 MillionNo Debt Outstanding and $27.1 million of Cash at Quarter-End Management Commentary – Cabell Lolmaugh, CEO “While hou...
- Thomas Vranken
Merus FIRST LOOK: 1Q25 results as expected, looking out toward ASCO up...
Merus announced its 1Q25 results, highlighting ongoing clinical trials and financial performance. The Ph2 trial of Peto in combination with Keytruda for head and neck cancer is progressing, with an update expected at ASCO 2025. The two Ph3 trials for head and neck cancer continue enrolling, with substantial enrolment expected by year-end 2025. With $ 638m in cash, Merus reiterates its cash runway into 2028. We reiterate our $ 59 TP/Buy.
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update May 2025: Removing Fugro – Adding Merus
The ongoing tariff war continues to create uncertainty for investors, with a trade embargo between the US and China. Although Europe has received a temporary reprieve, the prolonged situation could result in significant economic damage. We are maintaining a defensive stance in our Benelux Dynamic Top Pick List, as the Federal Reserve holds steady and the European Central Bank may continue lowering rates. Pessimism regarding the European industry has increased, though some US-based European compa...
Merus Announces Financial Results for the First Quarter 2025 and Provi...
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific ant...
Fluence Energy, Inc. Reports Second Quarter 2025 Results; Lowers Full ...
Fluence Energy, Inc. Reports Second Quarter 2025 Results; Lowers Full Year 2025 Guidance, Citing Decisions to Pause Certain U.S. Projects Due to Tariff Uncertainty ARLINGTON, Va., May 07, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and six months ended March 31, 2025. Financial Highlights for Fiscal Quarter ended March 31, 2025 Revenue of approximately $431.6 million, which represents...
American International Group Inc: 3 directors
Three Directors at American International Group Inc sold/sold after exercising options 77,959 shares at between 83.261USD and 83.574USD. The significance rating of the trade was 90/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionar...
Moody’s Ratings assigns Baa2 ratings to AIG’s senior notes
Company issuing $625 million five-year and $625 million 10-year notes New York , May 5, 2025 – Moody's Ratings (Moody's) has assigned Baa2 ratings to $625 million of five-year and $625 million of 10-year senior unsecured notes being issued by American International Group, Inc. (NYSE: AIG) off its mu...
- Jonathan Moreland
DHIL DIAMOND HILL INVESTMENT GROUP
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
SON SONOCO PRODUCTS COMPANY
TRS TRIMAS CORPORATION
TCBI TEXAS CAPITAL BANCSHARES INC.
TBK TRIUMPH BANCORP INC.
SIG SIGNET JEWELERS LIMITED
NBTB NBT BANCORP INC.
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
GNTX GENTEX CORPORATION
CDXS CODEXIS
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
BANC BANC OF CALIFORNIA INCORPORATED
SNWV SANUWAVE HEALTH
MRTN MARTEN TRANSPORT LTD.
WFT.. WEATHERFORD INTERNATIONAL PLC
NHC NATIONAL HEALTHCARE CORP.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MBIN MERCHANTS BANCORP
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
MCFT MASTERCRAFT BOAT HOLDINGS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
AVTR AVANTOR
FNLC INC.
DLHC FIRST BANCORP
TCBX INC (ME)
JMSB DALEIGH HOLDINGS CORP
MEGI THIRD COAST BANCSHARES INC
OBIO JOHN MARSHALL BANCORP INC
CVI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
PHIN ORCHESTRA BIOMED HOLDINGS INC
NBBK CVR ENERGY
DMA INC.
SUNS PHINIA INC
EVM NB BANCORP INC.
GF DESTRA MULTI ALTERNATIVE FUND
ECF SUNRISE REALTY TRUST
EATON VANCE INSD CALIF MUN BD FD
THE NEW GERMANY FUND
INC.
ELLSWORTH FUND LTD
- Jonathan Moreland
DHIL DIAMOND HILL INVESTMENT GROUP
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MBIN MERCHANTS BANCORP
NWPP NEW PEOPLES BANKSHARES INC.
MCFT MASTERCRAFT BOAT HOLDINGS
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
SCKT SOCKET MOBILE INC
ACRV ACRIVON THERAPEUTICS INC
OBIO ORCHESTRA BIOMED HOLDINGS INC
CVI CVR ENERGY
PHIN INC.
DMA PHINIA INC
EVM DESTRA MULTI ALTERNATIVE FUND
GF EATON VANCE INSD CALIF MUN BD FD
ECF THE NEW GERMANY FUND
INC.
ELLSWORTH FUND LTD
The Tile Shop to Host First Quarter 2025 Earnings Conference Call
The Tile Shop to Host First Quarter 2025 Earnings Conference Call MINNEAPOLIS, May 01, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone tiles, man-made and luxury vinyl tiles, setting and maintenance materials, and related accessories, today announced that the Company will release financial results for the first quarter ended March 31, 2025, at 7:00 a.m. Eastern Time on Thursday, May 8, 2025. The Company will host a conference call via webcast for investors and other interested parties beginning at 9:00 a.m. Eastern T...
NTR, a leading renewable energy specialist selects Fluence for Flagshi...
NTR, a leading renewable energy specialist selects Fluence for Flagship Finnish Battery Energy Storage System Fluence, a market leader in energy storage technology, selected to supply the 55 MW / 110 MWh battery system supporting FinGrid with critical system services DUBLIN and AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- NTR, a leading sustainable infrastructure investor and asset manager, has signed contracts with all key equipment and contractor partners for its ready-to-build Uusnivala battery energy storage system (BESS) project located in Nivala, Northern Ostrobothnia province, F...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
CDXS CODEXIS
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
BANC BANC OF CALIFORNIA INCORPORATED
MRTN MARTEN TRANSPORT LTD.
AVTR AVANTOR
TCBX INC.
GLSI THIRD COAST BANCSHARES INC
JMSB GREENWICH LIFESCIENCES INC
NBBK JOHN MARSHALL BANCORP INC
BHRB NB BANCORP INC.
DMA BURKE HERBERT FINANCIAL SERVICES CORP
DESTRA MULTI ALTERNATIVE FUND
- Research Team ACF
ACF Thematic Oncology Lung Cancer Cough LCC 25042025
Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.